In today’s highly cost-conscious Irish pharmaceutical marketplace, one of the greatest challenges for all stakeholders is how new products are funded.  For many companies with exciting new products, there can be a significant gap between IMB licence approval and confirmation of HSE reimbursement status. TCP Group has been working with many leading biotech and pharmaceutical companies to devise launch strategies for specialist products in a highly controlled manner, while also providing clear data on levels of prescribing and patient numbers.

TCP Group can take control of your specialist product supply chain, therefore enabling you to build up further pharmacoeconomic data to secure reimbursement. Some of the areas we have worked with the leading pharmaceutical companies are:

• Direct to patient distribution
• Risk share / Conditional reimbursement programmes
• Homecare patient support programmes

Talk to us today about your market access strategy for your specialist products.